title: Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.
abstract: There have been significant improvements in the detection and treatment of breast cancer in recent decades. However, there is still a need to develop more effective therapeutic techniques that are patient specific with reduced toxicity leading to further increases in patients' overall survival; the ongoing progress in understanding recurrence, resistant and spread also needs to be maintained. Better understanding of breast cancer pathology, molecular biology and progression as well as identification of some of the underlying factors involved in breast cancer tumourgenesis and metastasis has led to the identification of novel therapeutic targets. Over a number of years interest has risen in breast tumour kinase (Brk) also known as protein tyrosine kinase 6; the research field has grown and Brk has been described as a desirable therapeutic target in relation to tyrosine kinase inhibition as well as disruption of its kinase independent activity. This review will outline the current "state of play" with respect to targeted therapy for breast cancer, as well as discussing Brk's role in the processes underlying tumour development and metastasis and its potential as a therapeutic target in breast cancer.
authors.affiliation: Haroon A Hussain, Amanda J Harvey, Brunel Institute for Cancer Genetics and Pharmacogenomics, Biosciences, Brunel University (London), Uxbridge UB8 3PH, United Kingdom.
authors.forename: Haroon A
authors.initials: HA
authors.lastname: Hussain
authors.affiliation: Haroon A Hussain, Amanda J Harvey, Brunel Institute for Cancer Genetics and Pharmacogenomics, Biosciences, Brunel University (London), Uxbridge UB8 3PH, United Kingdom.
authors.forename: Amanda J
authors.initials: AJ
authors.lastname: Harvey
keywords: Breast neoplasms; Breast tumour kinase; Intracellular signaling peptides and proteins; Protein kinase inhibitors; Protein tyrosine kinase 6; Targeted molecular therapy
references.citation: Oncogene. 1994 Aug;9(8):2383-90
references.pmid: 8036022
references.citation: Oncogene. 2000 Aug 31;19(37):4273-82
references.pmid: 10980601
references.citation: Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819-23
references.pmid: 3024151
references.citation: Oncogenesis. 2012 May 07;1:e11
references.pmid: 23552639
references.citation: Cell Signal. 2008 Feb;20(2):432-42
references.pmid: 18077133
references.citation: Oncogene. 2003 Aug 7;22(32):5006-10
references.pmid: 12902983
references.citation: Mol Cancer Ther. 2012 Nov;11(11):2311-20
references.pmid: 22989419
references.citation: Front Oncol. 2013 Sep 23;3:250
references.pmid: 24069582
references.citation: Int J Cancer. 2001 Dec 15;94(6):774-82
references.pmid: 11745477
references.citation: J Cell Sci. 2001 Apr;114(Pt 7):1253-63
references.pmid: 11256992
references.citation: Oncogene. 2013 Sep 5;32(36):4304-12
references.pmid: 23027128
references.citation: J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
references.pmid: 16002463
references.citation: Oncogene. 2005 Aug 25;24(36):5656-64
references.pmid: 15870689
references.citation: Oncogene. 2004 Mar 18;23(12):2216-23
references.pmid: 14676834
references.citation: Clin Cancer Res. 2002 Feb;8(2):361-7
references.pmid: 11839650
references.citation: BMC Cell Biol. 2009 Oct 31;10:78
references.pmid: 19878579
references.citation: Tumour Biol. 2011 Oct;32(5):873-80
references.pmid: 21603980
references.citation: Cell. 2006 Nov 3;127(3):469-80
references.pmid: 17081971
references.citation: J Biomol NMR. 2001 Mar;19(3):291-2
references.pmid: 11330822
references.citation: Cancer Res. 2001 Sep 1;61(17):6583-91
references.pmid: 11522658
references.citation: Mol Pharmacol. 2007 Aug;72(2):248-58
references.pmid: 17456787
references.citation: Cancer Res. 2004 Jan 1;64(1):286-91
references.pmid: 14729636
references.citation: Oncogene. 2012 Oct 4;31(40):4372-83
references.pmid: 22231447
references.citation: Br J Cancer. 2007 Mar 12;96(5):801-7
references.pmid: 17299391
references.citation: Cancer Res. 2001 Oct 1;61(19):7196-203
references.pmid: 11585755
references.citation: Cancer Res. 2004 Jun 1;64(11):3981-6
references.pmid: 15173011
references.citation: Cancer Res. 2004 Sep 15;64(18):6652-9
references.pmid: 15374980
references.citation: Oncogene. 2006 Aug 10;25(35):4904-12
references.pmid: 16568091
references.citation: Cancer Res. 2008 Oct 1;68(19):7779-87
references.pmid: 18829532
references.citation: Cell Signal. 2013 Sep;25(9):1754-61
references.pmid: 23707532
references.citation: Biochem Biophys Res Commun. 2013 Feb 22;431(4):734-9
references.pmid: 23352614
references.citation: Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S135-44
references.pmid: 16113090
references.citation: Biochim Biophys Acta. 2010 Aug;1806(1):66-73
references.pmid: 20193745
references.citation: Br J Cancer. 2010 Aug 24;103(5):663-7
references.pmid: 20700126
references.citation: Curr Drug Targets. 2010 Aug;11(8):1000-17
references.pmid: 20426765
references.citation: J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):431-41
references.pmid: 19030970
references.citation: Cancer Res. 2001 Oct 1;61(19):7184-8
references.pmid: 11585753
references.citation: Oncogene. 2000 Nov 16;19(48):5471-6
references.pmid: 11114724
references.citation: J Biol Chem. 2010 Aug 20;285(34):26013-21
references.pmid: 20554524
references.citation: J Biol Chem. 2002 Sep 13;277(37):34634-41
references.pmid: 12121988
references.citation: J Cell Biol. 1994 Feb;124(4):619-26
references.pmid: 8106557
references.citation: Lab Invest. 1995 Jan;72(1):55-63
references.pmid: 7837791
references.citation: Cancer Res. 2007 May 1;67(9):4199-209
references.pmid: 17483331
references.citation: Cell Cycle. 2010 Mar 15;9(6):1043-50
references.pmid: 20237428
references.citation: Ann Oncol. 2007 Jun;18 Suppl 6:vi26-30
references.pmid: 17591827
references.citation: Am J Pathol. 2009 Sep;175(3):1226-34
references.pmid: 19661439
references.citation: Cell Cycle. 2005 Sep;4(9):1239-46
references.pmid: 16082217
references.citation: Gastroenterology. 2011 Oct;141(4):1371-80, 1380.e1-2
references.pmid: 21741923
references.citation: Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24
references.pmid: 14676101
references.citation: Br J Cancer. 2008 Oct 7;99(7):1089-95
references.pmid: 18781181
references.citation: Oncogene. 1997 Sep 18;15(12):1497-502
references.pmid: 9333026
references.citation: Int J Biochem Cell Biol. 2013 Dec;45(12):2832-42
references.pmid: 24148254
references.citation: Adv Exp Med Biol. 2007;608:101-12
references.pmid: 17993235
references.citation: Mol Cell Biol. 2004 Dec;24(24):10558-72
references.pmid: 15572663
references.citation: Breast Cancer Res. 2007;9(6):R79
references.pmid: 17997837
references.citation: Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8443-8
references.pmid: 8710890
references.citation: Oncologist. 2011;16 Suppl 1:12-9
references.pmid: 21278436
references.citation: Blood Cells Mol Dis. 2007 Sep-Oct;39(2):212-20
references.pmid: 17553709
references.citation: Cancer Res. 1992 Sep 1;52(17):4773-8
references.pmid: 1380891
references.citation: Oncogene. 1997 Aug 14;15(7):799-805
references.pmid: 9266966
references.citation: Genes Cancer. 2013 May;4(5-6):187-95
references.pmid: 24069506
references.citation: Nat Rev Cancer. 2009 Jan;9(1):28-39
references.pmid: 19104514
references.citation: Biochem J. 2012 Oct 15;447(2):313-20
references.pmid: 22849407
references.citation: Anticancer Drugs. 2004 Feb;15(2):107-11
references.pmid: 15075665
references.citation: Mol Cancer Res. 2013 Apr;11(4):381-92
references.pmid: 23364537
references.citation: Arch Dermatol Res. 2011 May;303(4):293-7
references.pmid: 21240512
references.citation: Physiol Genomics. 2012 Apr 15;44(8):455-69
references.pmid: 22395315
references.citation: J Cell Sci. 2008 Aug 1;121(Pt 15):2435-44
references.pmid: 18650496
references.citation: Oncologist. 2011;16(9):1203-14
references.pmid: 21880861
references.citation: J Pathol. 2014 Jan;232(2):219-29
references.pmid: 24105684
references.citation: J Cancer. 2011;2:324-8
references.pmid: 21716849
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2359-64
references.pmid: 19174523
references.citation: Br J Cancer. 1994 Aug;70(2):304-8
references.pmid: 8054279
references.citation: Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5
references.pmid: 21855335
references.citation: PLoS One. 2011 Mar 30;6(3):e14789
references.pmid: 21479203
references.citation: Semin Oncol. 2002 Jun;29(3):231-45
references.pmid: 12063676
references.citation: J Cell Sci. 2010 Jan 15;123(Pt 2):236-45
references.pmid: 20026641
references.citation: Exp Cell Res. 1999 Nov 25;253(1):78-87
references.pmid: 10579913
references.citation: Breast Cancer Res Treat. 2012 Jun;133(3):1049-56
references.pmid: 22418699
references.citation: Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12463-8
references.pmid: 18719096
references.citation: Mol Cancer Ther. 2007 Aug;6(8):2168-77
references.pmid: 17671085
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Breast Cancer Res. 2013 Oct 01;15(5):R92
references.pmid: 24286369
references.citation: Breast Cancer Res Treat. 2012 Jul;134(1):13-20
references.pmid: 22198412
references.citation: J Biol Chem. 2004 Jul 9;279(28):29700-8
references.pmid: 15056653
references.citation: J Pathol. 2005 Apr;205(5):592-6
references.pmid: 15685689
references.citation: PLoS One. 2010 Jul 23;5(7):e11729
references.pmid: 20668531
references.citation: J Biol Chem. 1996 Nov 29;271(48):30956-63
references.pmid: 8940083
references.citation: Int J Cancer. 2010 Dec 1;127(11):2723-31
references.pmid: 20162673
references.citation: Mol Cell Biol. 2006 Jul;26(13):4949-57
references.pmid: 16782882
references.citation: Cancer Res. 2008 Jan 1;68(1):152-61
references.pmid: 18172307
references.citation: Gastroenterology. 2009 Sep;137(3):945-54
references.pmid: 19501589
references.citation: Front Biosci. 2008 May 01;13:3906-12
references.pmid: 18508484
references.citation: Breast Cancer Res. 2011 Sep 17;13(5):R89
references.pmid: 21923922